| 1448959-31-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 1448959-31-6
• 化学式: C₁₀H₁₇NO₄S₂Si
• 分子量: 307.467
• InChiKey: GVLFZQWREICEMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18.0
• 可旋转键数：
  4.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  80.31
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  2-(3-ethoxy-4-isopropoxyphenyl)-2-(isoquinolin-6-ylamino)acetic hydrochloride 、 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(3-ethoxy-4-propan-2-yloxyphenyl)-2-(isoquinolin-6-ylamino)-N-(4-methylsulfonylphenyl)sulfonylacetamide
  参考文献：
  名称：

  Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors

  摘要：

  Aminoisoquinoline and isoquinoline groups have successfully replaced the more basic P1 benzamidine group of an acylsulfonamide factor Vila inhibitor. Inhibitory activity was optimized by the identification of additional hydrophobic and hydrophilic P' binding interactions. The molecular details of these interactions were elucidated by X-ray crystallography and molecular modeling. We also show that decreasing the basicity of the P1 group results in improved oral bioavailability in this chemotype. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.027

文献信息

• Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors
  作者：Peter W. Glunz、Xiaojun Zhang、Yan Zou、Indawati Delucca、Alexandra H. Nirschl、Xuhong Cheng、Carolyn A. Weigelt、Daniel L. Cheney、Anzhi Wei、Rushith Anumula、Joseph M. Luettgen、Alan R. Rendina、Mark Harpel、Gang Luo、Robert Knabb、Pancras C. Wong、Ruth R. Wexler、E. Scott Priestley

  DOI：10.1016/j.bmcl.2013.06.027

  日期：2013.9

  Aminoisoquinoline and isoquinoline groups have successfully replaced the more basic P1 benzamidine group of an acylsulfonamide factor Vila inhibitor. Inhibitory activity was optimized by the identification of additional hydrophobic and hydrophilic P' binding interactions. The molecular details of these interactions were elucidated by X-ray crystallography and molecular modeling. We also show that decreasing the basicity of the P1 group results in improved oral bioavailability in this chemotype. (C) 2013 Elsevier Ltd. All rights reserved.